J. Christiansen

发表

Multiplexed protein profiling on microarrays by rolling-circle amplification

S. Kingsmore, B. Grimwade, W. Shao, 2002, Nature Biotechnology.

ALK Inhibitor Response in Melanomas Expressing EML4-ALK Fusions and Alternate ALK Isoforms

Jennifer D. Hintzsche, R. Doebele, A. Tan, 2017, Molecular Cancer Therapeutics.

Genomic profiling of ER+ breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance

L. Garraway, X. Mu, R. Yelensky, 2017, Science Translational Medicine.

ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer

James X. Sun, P. Stephens, J. Hechtman, 2017, Journal of the National Cancer Institute.

Identification and characterization of a novel SCYL3-NTRK1 rearrangement in a colorectal cancer patient.

R. Bosotti, A. Isacchi, E. Valtorta, 2017, Oncotarget.

Detecting Gene Rearrangements in Patient Populations Through a 2-Step Diagnostic Test Comprised of Rapid IHC Enrichment Followed by Sensitive Next-Generation Sequencing

R. Shoemaker, Kyoung-Mee Kim, Jeeyun Lee, 2016, Applied immunohistochemistry & molecular morphology : AIMM.

Intratumoral heterogeneity and TERT promoter mutations in progressive/higher-grade meningiomas

H. Wakimoto, D. Cahill, P. Brastianos, 2017, Oncotarget.

NTRK1 rearrangement in colorectal cancer patients: evidence for actionable target using patient-derived tumor cell line

Su Jin Lee, S. J. Lee, Joon-Oh Park, 2015, Oncotarget.

NTRK1 rearrangement in colorectal cancer patients: evidence for actionable target using patient-derived tumor cell line

Woo, Joon, Zachary, 2015, Oncotarget.

RET fusions in a small subset of advanced colorectal cancers at risk of being neglected

A. Drilon, F. Nicolantonio, A. Bardelli, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Detecting NTRK, ROS1, and ALK gene fusions in gastrointestinal tumor patients.

P. Pauwels, E. Chiorean, P. Multani, 2017 .

Evaluating Targeted Next-Generation Sequencing (NGS) Assays and Reference Materials for NTRK Fusion Detection.

Weei‐Yuarn Huang, C. B. Chung, Zhaolin Xu, 2021, The Journal of molecular diagnostics : JMD.

MET gene amplification is a mechanism of resistance to entrectinib in ROS1+ NSCLC

T. Wilson, R. Doebele, A. Le, 2022, Thoracic cancer.

What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC)

M. Ladanyi, M. Berger, A. Drilon, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Molecular Profiling of Mammary Analog Secretory Carcinoma Revealed a Subset of Tumors Harboring a Novel ETV6-RET Translocation: Report of 10 Cases

N. Rupp, M. Hyrcza, I. Weinreb, 2018, The American journal of surgical pathology.

Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).

A. Drilon, S. Ou, A. Shaw, 2017, Cancer discovery.

Acquired Resistance to KRASG12C Inhibition in Cancer.

P. Jänne, D. Root, R. Heist, 2021, The New England journal of medicine.

Colonic Adenocarcinomas Harboring NTRK Fusion Genes

E. Chmielik, A. Hartmann, C. Haglund, 2019, The American journal of surgical pathology.

Genomic Analysis of Posterior Fossa Meningioma Demonstrates Frequent AKT1 E17K Mutations in Foramen Magnum Meningiomas

D. Cahill, M. Frosch, P. Brastianos, 2019, Journal of Neurological Surgery Part B: Skull Base.

DMD genomic deletions characterize a subset of progressive/higher-grade meningiomas with poor outcome

Julie M. Batten, S. Carter, A. Iafrate, 2018, Acta Neuropathologica.

Development and standardization of multiplexed antibody microarrays for use in quantitative proteomics

LT Perlee, J Christiansen, R Dondero, 2004, Proteome Science.

Standardization of HER2 immunohistochemistry in breast cancer by automated quantitative analysis.

Dylan Reilly, Robert Pinard, Christine Williams, 2009, Archives of pathology & laboratory medicine.

Acral Lentiginous Melanoma Harboring a ROS1 Gene Fusion With Clinical Response to Entrectinib.

R. Doebele, K. Lewis, J. Christiansen, 2017, JCO precision oncology.

Colorectal Adenocarcinomas Harboring ALK Fusion Genes

A. Hartmann, A. Agaimy, J. Kopczyński, 2020, The American journal of surgical pathology.

Activity of Entrectinib in a Patient With the First Reported NTRK Fusion in Neuroendocrine Cancer.

P. Multani, J. Christiansen, D. Sigal, 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

Development of an Unsupervised Pixel-based Clustering Algorithm for Compartmentalization of Immunohistochemical Expression Using Automated QUantitative Analysis

Robert Pinard, Christine Williams, Mark D Gustavson, 2009, Applied immunohistochemistry & molecular morphology : AIMM.

Response to Entrectinib in Differentiated Thyroid Cancer With a ROS1 Fusion

P. Multani, J. Christiansen, Stephen V. Liu, 2017, JCO precision oncology.

Identification and characterization of a novel SCYL3-NTRK1 rearrangement in a colorectal cancer patient

R. Bosotti, A. Isacchi, E. Valtorta, 2017, Oncotarget.

Abstract A173: Potent anti-tumor activity of entrectinib in patient-derived models harboring oncogenic gene rearrangements of NTRKs

R. Shoemaker, A. Bardelli, Kyoung-Mee Kim, 2015 .

Genomic profiling of ER+ breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance

L. Garraway, X. Mu, R. Yelensky, 2017, Science Translational Medicine.

Extrachromosomal DNA (ecDNA) carrying amplified oncogenes as a biomarker for insensitivity to pembrolizumab treatment in gastric cancer patients.

V. Bafna, R. Verhaak, P. Mischel, 2020 .